Skip to main content
SpringerLink
Log in

Targeted Therapies for Gastric Cancer

Current Status

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Gastric cancer represents one of the most common cancers internationally. Unfortunately the majority of patients still present at an advanced stage, and despite advances in diagnostic and treatment strategies, outcomes still remain poor with high mortality rates despite a decline in incidence.

Whilst the utility of classical chemotherapy agents has been explored thoroughly (and continues to be investigated, alone or in various combinations), advances have been slow and the efficacy of these agents has reached a plateau. As such, the focus of recent study has shifted toward developing a greater understanding of the molecular biology of carcinogenesis and the cancer cell phenotype, and, in turn, the development of rationally designed drugs that target molecular aberrancies in signal transduction pathways specific to gastric cancer. These targets include circulating growth and angiogenic factors, cell surface receptors, and other molecules that comprise downstream intracellular signalling pathways, including receptor tyrosine kinases. Therapeutic advances in this area significantly lag behind other solid organ malignancies such as breast and colorectal cancer.

This article reviews the role of targeted therapies in gastric cancer, including rationale and mechanism of action, current and emerging data, as single-agent therapy or in combination regimens. A recently published randomized phase III trial supporting the use of trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2)/neu monoclonal antibody, in a selected population of patients is discussed. Therapies that have been evaluated in phase II trials are also reviewed, as well as promising new therapies currently being investigated in preclinical or phase I studies. There is optimism that targeted therapies, whether as single-agent therapy or in combination with traditional therapies, including chemotherapy, radiotherapy and surgery, may yet have an impact on improvement of the overall prognosis of gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006 May 10; 24(14): 2137–50

    Article  PubMed  Google Scholar 

  2. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975–2007 [online]. Available from URL: http://seer.cancer.gov/csr/1975_2007/ (based on November 2009 SEER data submission, posted to the SEER website, 2010) [Accessed 2010 Nov 22]

  3. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14 Suppl. 2: ii31–6

    Article  PubMed  Google Scholar 

  4. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 2010 Nov; 26(6): 640–6

    Article  PubMed  Google Scholar 

  5. Mlkvy P. Multimodal therapy of gastric cancer. Dig Dis 2010; 28(4-5): 615–8

    Article  PubMed  Google Scholar 

  6. Gianni L, Panzini I, Tassinari D, et al. Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol 2001 Aug; 12(8): 1178–80

    PubMed  CAS  Google Scholar 

  7. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993 Aug; 11(8): 1441–7

    PubMed  CAS  Google Scholar 

  8. Janunger KG, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40(2–3): 309–26

    Article  PubMed  CAS  Google Scholar 

  9. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials — a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000 Jul; 11(7): 837–43

    Article  PubMed  CAS  Google Scholar 

  10. Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002 Jan–Feb; 88(1): 21–7

    PubMed  CAS  Google Scholar 

  11. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010 May 5; 303(17): 1729–37

    Article  PubMed  CAS  Google Scholar 

  12. Macdonald JS, Smalley SR, Benedetti J, et al. Chemo-radiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001 Sep 6; 345(10): 725–30

    Article  PubMed  CAS  Google Scholar 

  13. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006 Jul 6; 355(1): 11–20

    Article  PubMed  CAS  Google Scholar 

  14. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999 Apr; 80(1-2): 269–72

    Article  PubMed  CAS  Google Scholar 

  15. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997 Jan; 15(1): 261–7

    PubMed  CAS  Google Scholar 

  16. Icli F, Celik I, Aykan F, et al. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer 1998 Dec 15; 83(12): 2475–80

    CAS  Google Scholar 

  17. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000 Jul; 18(14): 2648–57

    PubMed  CAS  Google Scholar 

  18. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007 Aug 1; 25(22): 3210–6

    Article  PubMed  CAS  Google Scholar 

  19. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007 Aug 1;25(22): 3205–9

    Article  PubMed  CAS  Google Scholar 

  20. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006 Nov 1; 24(31): 4991–7

    Article  PubMed  CAS  Google Scholar 

  21. Honecker F, Kollmannsberger C, Quietzsch D, et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anti-cancer Drugs 2002 Jun; 13(5): 497–503

    Article  PubMed  CAS  Google Scholar 

  22. Kang GH, Kim GS, Lee HR, et al. A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer. Cancer Res Treat 2008 Sep; 40(3): 106–10

    Article  PubMed  Google Scholar 

  23. Kang HJ, Chang HM, Kim TW, et al. A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer 2008 Jan 29; 98(2): 316–22

    Article  PubMed  CAS  Google Scholar 

  24. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000 Aug; 83(4): 458–62

    Article  PubMed  CAS  Google Scholar 

  25. Hejna M, Raderer M, Zacherl J, et al. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2. 001. Anticancer Drugs 2008 Jun; 19(5): 535–9

    CAS  Google Scholar 

  26. Kim JG, Sohn SK, Chae YS, et al. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. Br J Cancer 2008 Feb 12; 98(3): 542–6

    Article  PubMed  CAS  Google Scholar 

  27. Kim YS, Hong J, Sym SJ, et al. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat Mar 2010; 42(1): 24–9

    Article  Google Scholar 

  28. Lee HH, Hur H, Kim SH, et al. Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat Mar 2010; 42(1): 18–23

    Article  Google Scholar 

  29. Luo HY, Xu RH, Wang F, et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 2010; 56(2): 94–100

    Article  PubMed  CAS  Google Scholar 

  30. Richards D, McCollum D, Wilfong L, et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastro-esophageal junction. Ann Oncol 2008 Jan; 19(1): 104–8

    Article  PubMed  CAS  Google Scholar 

  31. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008 Mar 20; 26(9): 1435–42

    Article  PubMed  CAS  Google Scholar 

  32. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008 Jan 3; 358(1): 36–46

    Article  PubMed  CAS  Google Scholar 

  33. Kanat O, Evrensel T, Manavoglu O, et al. Single-agent ir-inotecan as second-line treatment for advanced gastric cancer. Tumori 2003 Jul–Aug; 89(4): 405–7

    PubMed  CAS  Google Scholar 

  34. Kohne CH, Catane R, Klein B, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003 Sep 15; 89(6): 997–1001

    Article  PubMed  CAS  Google Scholar 

  35. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002 Feb 1; 94(3): 641–6

    Article  PubMed  CAS  Google Scholar 

  36. Di Lauro L, Nunziata C, Arena MG, et al. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 2007 Sep 3; 97(5): 593–7

    Article  PubMed  CAS  Google Scholar 

  37. Enzinger PC, Ryan DP, Clark JW, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009 Mar; 20(3): 475–80

    Article  PubMed  CAS  Google Scholar 

  38. Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004 Jan; 15(1): 64–9

    Article  PubMed  CAS  Google Scholar 

  39. Baek JH, Kim JG, Jeon SB, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2006 May 22; 94(10): 1407–11

    Article  PubMed  CAS  Google Scholar 

  40. Burge ME, Smith D, Topham C, et al. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer 2006 May 8; 94(9): 1281–6

    Article  PubMed  CAS  Google Scholar 

  41. Moehler M, Haas U, Siebler J, et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003 Sep; 14(8): 645–50

    Article  PubMed  CAS  Google Scholar 

  42. Gubanski M, Johnsson A, Fernebro E, et al. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010 Aug; 13(3): 155–61

    Article  PubMed  CAS  Google Scholar 

  43. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008 Aug; 19(8): 1450–7

    Article  PubMed  CAS  Google Scholar 

  44. Baize N, Abakar-Mahamat A, Mounier N, et al. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol 2009 Aug; 64(3): 549–55

    Article  PubMed  CAS  Google Scholar 

  45. Chun JH, Kim HK, Lee JS, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005 Apr; 28(2): 188–94

    Article  PubMed  CAS  Google Scholar 

  46. Kim JG, Sohn SK, Kim DH, et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68(2–3): 190–5

    Article  PubMed  CAS  Google Scholar 

  47. Kang YK, Ryu MH, Yoo C, et al. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2011; 67(6): 1435–43

    Article  PubMed  CAS  Google Scholar 

  48. Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 2000 Nov; 18(4): 331–42

    Article  PubMed  CAS  Google Scholar 

  49. Shirasaka T, Yamamitsu S, Tsuji A, et al. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000 Nov; 18(4): 315–29

    Article  PubMed  CAS  Google Scholar 

  50. Chao Y, Li CP, Chao TY, et al. An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. Br J Cancer 2006 Jul 17; 95(2): 159–63

    Article  PubMed  CAS  Google Scholar 

  51. Inokuchi M, Yamashita T, Yamada H, et al. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006 Apr 24; 94(8): 1130–5

    Article  PubMed  CAS  Google Scholar 

  52. Jeen YT, Yoon SY, Shin SW, et al. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 2001 Jun 15;91(12): 2288–93

    Article  PubMed  CAS  Google Scholar 

  53. Kim YH, Cheong SK, Lee JD, et al. Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol 1996 Apr; 19(2): 212–6

    Article  PubMed  CAS  Google Scholar 

  54. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000 Apr; 58(3): 191–7

    Article  PubMed  CAS  Google Scholar 

  55. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008 Mar; 9(3): 215–21

    Article  PubMed  CAS  Google Scholar 

  56. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003 Dec 15; 89(12): 2207–12

    Article  PubMed  CAS  Google Scholar 

  57. Mochiki E, Ohno T, Kamiyama Y, et al. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 2006 Dec 18; 95(12): 1642–7

    Article  PubMed  CAS  Google Scholar 

  58. Narahara H, Fujitani K, Takiuchi H, et al. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 2008; 74(1-2): 37–41

    Article  PubMed  CAS  Google Scholar 

  59. Oh SC, Park KH, Choi IK, et al. Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer. Br J Cancer 2005 Mar 14; 92(5): 827–31

    Article  PubMed  CAS  Google Scholar 

  60. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003 Jan 1; 21(1): 54–9

    Article  PubMed  CAS  Google Scholar 

  61. Park SR, Kong SY, Rhee J, et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol 2011 Apr; 22(4): 890–6

    Article  PubMed  CAS  Google Scholar 

  62. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999 Oct; 57(3): 202–10

    Article  PubMed  CAS  Google Scholar 

  63. Woo IS, Moon DH, Shim BY, et al. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Jpn J Clin Oncol 2005 Jan; 35(1): 13–7

    Article  PubMed  Google Scholar 

  64. Yamaguchi K, Shimamura T, Hyodo I, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006 Jun 19; 94(12): 1803–8

    Article  PubMed  CAS  Google Scholar 

  65. Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006 Jun 1; 12 (11 Pt 1): 3402–7

    Article  PubMed  CAS  Google Scholar 

  66. Ajani JA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006 Feb 1; 24(4): 663–7

    Article  PubMed  CAS  Google Scholar 

  67. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010 Mar 20; 28(9): 1547–53

    Article  PubMed  CAS  Google Scholar 

  68. Chollet P, Schoffski P, Weigang-Kohler K, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer: a trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003 Jun; 39(9): 1264–70

    Article  PubMed  CAS  Google Scholar 

  69. Ravaud A, Borner M, Schellens JH, et al. UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer: an Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. Eur J Cancer 2001 Sep; 37(13): 1642–7

    Article  PubMed  CAS  Google Scholar 

  70. Boonstra J, Rijken P, Humbel B, et al. The epidermal growth factor. Cell Biol Int 1995 May; 19(5): 413–30

    Article  PubMed  CAS  Google Scholar 

  71. Pai R, Tarnawski A. Signal transduction cascades triggered by EGF receptor activation: relevance to gastric injury repair and ulcer healing. Dig Dis Sci 1998 Sep; 43 (9 Suppl.): 14–22S

    Google Scholar 

  72. Patel D, Bassi R, Hooper A, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol 2009 Jan; 34(1): 25–32

    PubMed  CAS  Google Scholar 

  73. Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010 Mar 1; 16(5): 1509–19

    Article  PubMed  CAS  Google Scholar 

  74. Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839. Semin Oncol 2001 Oct; 28 (5 Suppl. 16): 56–66

    Article  PubMed  CAS  Google Scholar 

  75. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010 May; 36(3): 235–48

    Article  PubMed  CAS  Google Scholar 

  76. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008 Feb; 19(2): 99–113

    Article  PubMed  CAS  Google Scholar 

  77. Yasui W, Hata J, Yokozaki H, et al. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer 1988 Feb 15; 41(2): 211–7

    Article  PubMed  CAS  Google Scholar 

  78. Yonemura Y, Sugiyama K, Fujimura T, et al. Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma. Oncology 1989; 46(3): 158–61

    Article  PubMed  CAS  Google Scholar 

  79. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006 Aug; 33(4): 369–85

    Article  PubMed  CAS  Google Scholar 

  80. Luo HY, Wei W, Shi YX, et al. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol Rep 2010 Jun; 23(6): 1735–45

    PubMed  CAS  Google Scholar 

  81. Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008 Feb 1; 70(2): 391–5

    Article  PubMed  CAS  Google Scholar 

  82. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007 Mar; 18(3): 510–7

    Article  PubMed  CAS  Google Scholar 

  83. Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line meta-static gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010 Feb 2; 102(3): 500–5

    Article  PubMed  CAS  Google Scholar 

  84. Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011; 29(2): 366–73

    Article  PubMed  CAS  Google Scholar 

  85. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009 Oct 20; 101(8): 1261–8

    Article  PubMed  CAS  Google Scholar 

  86. Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011; 22(6): 1358–66

    Article  PubMed  CAS  Google Scholar 

  87. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001 May; 7(5): 1459–65

    PubMed  CAS  Google Scholar 

  88. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001 Oct; 7(10): 2958–70

    PubMed  CAS  Google Scholar 

  89. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [published erratum appears in J Clin Oncol 2004; 22 (23): 4811].J Clin Oncol 2003 Jun 15; 21(12): 2237–46

    Article  PubMed  CAS  Google Scholar 

  90. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 Oct 22; 290(16): 2149–58

    Article  PubMed  CAS  Google Scholar 

  91. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep 3; 361(10): 947–57

    Article  PubMed  CAS  Google Scholar 

  92. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353(2): 123–32

    Article  PubMed  CAS  Google Scholar 

  93. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 May 20; 25(15): 1960–6

    Article  PubMed  CAS  Google Scholar 

  94. Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009 Jun; 10(5): 470–81

    Article  PubMed  CAS  Google Scholar 

  95. Park JK, Lee SH, Kang JH, et al. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs 2004 Sep; 15(8): 809–18

    Article  PubMed  CAS  Google Scholar 

  96. Kishida O, Miyazaki Y, Murayama Y, et al. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 2005 Jun; 55(6): 584–94

    Article  PubMed  CAS  Google Scholar 

  97. Doi T, Koizumi W, Siena S et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD 1839) in pretreated patients with metastatic gastric cancer [abstract no. 1036]. Proc Am Soc Clin Oncol 2003; 22: 258

    Google Scholar 

  98. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006 Oct 20; 24(30): 4922–7

    Article  PubMed  CAS  Google Scholar 

  99. Koeppen HK, Wright BD, Burt AD, et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 2001 Feb; 38(2): 96–104

    Article  PubMed  CAS  Google Scholar 

  100. Jaehne J, Urmacher C, Thaler HT, et al. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118(6): 474–9

    Article  PubMed  CAS  Google Scholar 

  101. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Jan 9; 235(4785): 177–82

    Article  PubMed  CAS  Google Scholar 

  102. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value — conclusions from 924 cases of two independent series. Cell Oncol 2010; 32(1–2): 57–65

    PubMed  Google Scholar 

  103. Im SA, Lee KE, Nam E, et al. Potential prognostic significance of p185 (HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005 Nov–Dec;91(6): 513–21

    PubMed  CAS  Google Scholar 

  104. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001; 12 Suppl. 1: S35–41

    Article  PubMed  Google Scholar 

  105. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007 Jul 5; 357(1): 39–51

    Article  PubMed  CAS  Google Scholar 

  106. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353(16): 1659–72

    Article  PubMed  CAS  Google Scholar 

  107. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353(16): 1673–84

    Article  PubMed  CAS  Google Scholar 

  108. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 Jan 6; 369(9555): 29–36

    Article  PubMed  CAS  Google Scholar 

  109. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-over-expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999 Sep; 17(9): 2639–48

    PubMed  CAS  Google Scholar 

  110. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 2001 Mar 15; 344(11): 783–92

    Article  PubMed  CAS  Google Scholar 

  111. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002 Feb 1; 20(3): 719–26

    Article  PubMed  CAS  Google Scholar 

  112. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002 Mar 1; 20(5): 1215–21

    Article  PubMed  CAS  Google Scholar 

  113. Matsui Y, Inomata M, Tojigamori M, et al. Suppression of tumor growth in human gastric cancer with HER2 over-expression by an anti-HER2 antibody in a murine model. Int J Oncol 2005 Sep; 27(3): 681–5

    PubMed  CAS  Google Scholar 

  114. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Anti-tumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007 May; 59(6): 795–805

    Article  PubMed  CAS  Google Scholar 

  115. Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008 Jan; 32(1): 89–95

    PubMed  Google Scholar 

  116. Li XL, Yi SQ, Xu JM, et al. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-fluorouracil or cisplatin on gastric cancer cell lines. Cancer Invest 2010 Dec; 28(10): 1038–47

    Article  PubMed  CAS  Google Scholar 

  117. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet Aug 28; 376 (9742): 687–97

  118. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001 Dec; 1(2): 85–94

    PubMed  CAS  Google Scholar 

  119. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006 Dec 28; 355(26): 2733–43

    Article  PubMed  CAS  Google Scholar 

  120. Kim JW, Kim HP, Im SA, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008 Dec 18; 272(2): 296–306

    Article  PubMed  CAS  Google Scholar 

  121. Tanizaki J, Okamoto I, Takezawa K, et al. Synergistic anti-tumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 2010 May; 9(5): 1198–207

    Article  PubMed  CAS  Google Scholar 

  122. Iqbal S, Goldman B, Fengolio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. Epub 2011 May 20

  123. GlaxoSmithKline. LOGiC — Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: a phase III global, blinded study designed to evaluate clinical end-points and safety of chemotherapy plus lapatinib. [ClinicalTrials.gov identifier NCT00680901]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 17]

  124. Folkman J. What is the evidence that tumors are angio-genesis dependent? J Natl Cancer Inst 1990 Jan 3; 82(1): 4–6

    Article  PubMed  CAS  Google Scholar 

  125. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36(2): 127–37

    Article  PubMed  CAS  Google Scholar 

  126. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999 Sep; 56(3): 794–814

    Article  PubMed  CAS  Google Scholar 

  127. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106(4): 148–56

    Article  PubMed  CAS  Google Scholar 

  128. Yamamoto S, Yasui W, Kitadai Y, et al. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int 1998 Jul; 48(7): 499–506

    Article  PubMed  CAS  Google Scholar 

  129. Kimura H, Konishi K, Nukui T, et al. Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol 2001 Jan; 76(1): 31–6

    Article  PubMed  CAS  Google Scholar 

  130. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996 Mar 1; 77(5): 858–63

    Article  PubMed  CAS  Google Scholar 

  131. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998 Dec; 34(13): 2041–5

    Article  PubMed  CAS  Google Scholar 

  132. Maeda K, Kang SM, Onoda N, et al. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology 1998 Nov–Dec; 55(6): 594–9

    Article  PubMed  CAS  Google Scholar 

  133. Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000 May 29; 153(1–2): 7–12

    Article  PubMed  CAS  Google Scholar 

  134. Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010; 15(8): 819–25

    Article  PubMed  CAS  Google Scholar 

  135. Geiger-Gritsch S, Stollenwerk B, Miksad R, et al. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010; 15(11): 1179–91

    Article  PubMed  CAS  Google Scholar 

  136. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstract no. LBA4007]. J Clin Oncol 2010; 28 Suppl.: 18s

    Article  CAS  Google Scholar 

  137. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006 Nov 20; 24(33): 5201–6

    Article  PubMed  CAS  Google Scholar 

  138. El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastro-esophageal junction cancers. Ann Oncol 2010 Oct; 21(10): 1999–2004

    Article  PubMed  CAS  Google Scholar 

  139. Enzinger PC, Ryan DP, Regan EM, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer [abstract no. 4552]. J Clin Oncol 2008; 26 (15S May 20 Suppl.): 4552

    Google Scholar 

  140. Kelsen D, Jhawer M, Ilson D, et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial [abstract no. 4512]. J Clin Oncol 2009; 27 (15S May 20 Suppl.): 4512

    Google Scholar 

  141. Dal Lago L, D’Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008 Aug; 13(8): 845–58

    Article  CAS  Google Scholar 

  142. Tesei A, Leonetti C, Zupi G, et al. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med. Epub 2009 Dec 8

  143. Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. Epub 2010 Sep 14

  144. Sun W, Powell M, O’Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010 Jun 20; 28(18): 2947–51

    Article  PubMed  CAS  Google Scholar 

  145. Cortes-Funes H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin Transl Oncol 2009 Jun; 11(6): 349–55

    Article  PubMed  CAS  Google Scholar 

  146. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. Epub 2010 May 12

  147. Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009 Apr; 14(4): 378–90

    Article  PubMed  CAS  Google Scholar 

  148. Lyros O, Mueller A, Heidel F, et al. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. IntJ Cancer 2010 Sep 1; 127(5): 1197–208

    Article  CAS  Google Scholar 

  149. McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004 Sep; 3(9): 1041–8

    PubMed  CAS  Google Scholar 

  150. Yuan R, Kay A, Berg WJ, et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009; 2: 45

    Article  PubMed  CAS  Google Scholar 

  151. Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007 Apr 15; 120(8): 1803–10

    Article  PubMed  CAS  Google Scholar 

  152. An JY, Kim KM, Choi MG, et al. Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 2010 Jun 15; 126(12): 2904–13

    PubMed  CAS  Google Scholar 

  153. Taguchi F, Kodera Y, Katanasaka Y, et al. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs. Epub 2010 Jun 8

  154. Cejka D, Preusser M, Fuereder T, et al. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 2008 Nov-Dec; 28(6A): 3801–8

    PubMed  CAS  Google Scholar 

  155. Lee KH, Hur HS, Im SA, et al. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 2010 Dec 18; 299(1): 22–8

    Article  PubMed  CAS  Google Scholar 

  156. Matsuzaki T, Yashiro M, Kaizaki R, et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009 Dec; 100(12): 2402–10

    Article  PubMed  CAS  Google Scholar 

  157. Fuereder T, Jaeger-Lansky A, Hoeflmayer D, et al. mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett 2010 Oct 28; 296(2): 249–56

    Article  PubMed  CAS  Google Scholar 

  158. Yamada Y, Doi T, Muro K, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010 Apr 10; 28(11): 1904–10

    Article  PubMed  CAS  Google Scholar 

  159. GRANITE-1: safety and efficacy of RAD001 (Everolimus) monotherapy plus best supportive care in patients with advanced gastric cancer (AGC). [ClinicalTrials.gov identifier NCT00879333]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 5]

  160. GRANITE-2: a randomized, double blind study evaluating paclitaxel with and without RAD001 in patients with gastric carcinoma after prior chemotherapy (AIO-STO-0111). [ClinicalTrials.gov identifier NCT01248403]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 5]

  161. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999 May 1; 85(9): 1894–902

    PubMed  CAS  Google Scholar 

  162. Jhawer MP, Kindler HL, Wainberg ZA, et al. Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): interim results of a multicenter phase II study. J Clin Oncol 2008; 26(15S): 4572

    Google Scholar 

  163. Jhawer M, Kindler HL, Wainberg Z, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study [abstract]. J Clin Oncol 2009; 27(15S): 4502

    Google Scholar 

  164. Gollob JA, Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006 Aug; 33(4): 392–406

    Article  PubMed  CAS  Google Scholar 

  165. Yang S, Ngo VC, Lew GB, et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther 2009 Sep; 8(9): 2537–45

    Article  PubMed  CAS  Google Scholar 

  166. Yoon YK, Kim HP, Han SW, et al. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 2009 Sep; 8(9): 2526–36

    Article  PubMed  CAS  Google Scholar 

  167. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000 Mar 1; 92(5): 376–87

    Article  PubMed  CAS  Google Scholar 

  168. Jung C, Motwani M, Kortmansky J, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003 Dec 1; 9 (16 Pt 1): 6052–61

    PubMed  CAS  Google Scholar 

  169. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001 Aug; 7(8): 2527–36

    PubMed  CAS  Google Scholar 

  170. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999 Jul; 5(7): 1876–83

    PubMed  CAS  Google Scholar 

  171. Motwani M, Rizzo C, Sirotnak F, et al. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003 Jun; 2(6): 549–55

    PubMed  CAS  Google Scholar 

  172. Rathkopf D, Dickson MA, Feldman DR, et al. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 2009 Dec 1; 15(23): 7405–11

    Article  PubMed  CAS  Google Scholar 

  173. Schwartz GK, Farsi K, Maslak P, et al. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 1997 Sep; 3(9): 1467–72

    PubMed  CAS  Google Scholar 

  174. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002 Dec; 50(6): 465–72

    Article  PubMed  CAS  Google Scholar 

  175. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001 Apr 1; 19(7): 1985–92

    PubMed  CAS  Google Scholar 

  176. Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 2010 Mar 1; 16(5): 1662–72

    Article  PubMed  CAS  Google Scholar 

  177. Yashiro M, Shinto O, Nakamura K, et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer Feb 15; 126 (4): 1004-16

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the contents of this review. No other persons have made substantial contributions to this work.

Author information

Authors and Affiliations

  1. Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, Melbourne, VIC, 8006, Australia

    Jaclyn Yoong

  2. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia

    Michael Michael &  Trevor Leong

Authors
  1. Jaclyn Yoong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Michael
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Trevor Leong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trevor Leong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoong, J., Michael, M. & Leong, T. Targeted Therapies for Gastric Cancer. Drugs 71, 1367–1384 (2011). https://doi.org/10.2165/11592530-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11592530-000000000-00000

Keywords

Search

Navigation